Nanoparticles and the immune system.

Today nanotechnology is finding growing applications in industry, biology, and medicine. The clear benefits of using nanosized products in various biological and medical applications are often challenged by concerns about the lack of adequate data regarding their toxicity. One area of interest involves the interactions between nanoparticles and the components of the immune system. Nanoparticles can be engineered to either avoid immune system recognition or specifically inhibit or enhance the immune responses. We review herein reported observations on nanoparticle-mediated immunostimulation and immunosuppression, focusing on possible theories regarding how manipulation of particle physicochemical properties can influence their interaction with immune cells to attain desirable immunomodulation and avoid undesirable immunotoxicity.

[1]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[2]  Magdalena Plebanski,et al.  Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. , 2006, Methods.

[3]  I. Shin,et al.  The effect of gene therapy using CTLA4Ig/silica‐nanoparticles on canine experimental autoimmune thyroiditis , 2008, The journal of gene medicine.

[4]  T. Ishida,et al.  Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[5]  A. V. Shepelev,et al.  [Immunostimulating effect of water-soluble fullerene derivatives--perspective adjuvants for a new generation of vaccine]. , 1999, Doklady Akademii nauk.

[6]  J. Irache,et al.  Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  John D Lambris,et al.  Is complement good or bad for cancer patients? A new perspective on an old dilemma. , 2009, Trends in immunology.

[8]  B. Erlanger,et al.  Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Tomii,et al.  Production of anti-platelet-activating factor antibodies by the use of colloidal gold as carrier. , 1991, Japanese journal of medical science & biology.

[10]  T. Ishida,et al.  Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Taro Shimizu,et al.  PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Olausson,et al.  Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. , 2003, The Journal of surgical research.

[13]  S M Moghimi,et al.  Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines. , 2009, Molecular immunology.

[14]  W. Samlowski,et al.  Effect of ionizing radiation on thymic epithelial cell function. I. Radiation-spared thymic epithelial grafts expedite the recovery of T cell function in lethally irradiated and fetal liver reconstituted mice. , 1988, Journal of Immunology.

[15]  Jian Qin,et al.  The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. , 2006, Nano letters.

[16]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[17]  Robert J. Lee,et al.  Antitumor activity of G3139 lipid nanoparticles (LNPs). , 2009, Molecular pharmaceutics.

[18]  B. Braden,et al.  X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60). , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[20]  Krishnendu Roy,et al.  Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy , 1999, Nature Medicine.

[21]  J. McKearn,et al.  Biochemical and Immunological Properties of Cytokines Conjugated to Dendritic Polymers , 2004, Biomedical microdevices.

[22]  Craig A. Poland,et al.  Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. , 2008, Nature nanotechnology.

[23]  Rainer H Müller,et al.  Lipid nanoparticles for parenteral delivery of actives. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  David Leong,et al.  Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. , 2007, Molecular pharmaceutics.

[25]  A. Esquifino,et al.  Effect of cadmium on lymphocyte subsets distribution in thymus and spleen , 2003, Journal of Physiology and Biochemistry.

[26]  J. Kreuter.  Nanoparticles as adjuvants for vaccines. , 1995, Pharmaceutical biotechnology.

[27]  T. Dutta,et al.  Investigations on the toxicological profile of functionalized fifth‐generation poly(propylene imine) dendrimer , 2006, The Journal of pharmacy and pharmacology.

[28]  M. Sarbolouki,et al.  Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. , 2006, Journal of biotechnology.

[29]  Koji Kariya-city Aichi-pref. Tanaka,et al.  Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[30]  E. Untersmayr,et al.  Allergen‐loaded biodegradable poly(d,l‐lactic‐co‐glycolic) acid nanoparticles down‐regulate an ongoing Th2 response in the BALB/c mouse model , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[31]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.

[32]  H. Kohno,et al.  Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. , 2006, Experimental eye research.

[33]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[34]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[35]  J. Irache,et al.  Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. , 2007, Vaccine.

[36]  R. Müller,et al.  Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. , 2002, International journal of pharmaceutics.

[37]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[38]  V. Romanova,et al.  Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins. , 2000, Doklady biochemistry : proceedings of the Academy of Sciences of the USSR, Biochemistry section.

[39]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[40]  T. Ishida,et al.  Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[41]  M. Socinski,et al.  Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors , 2007, Cancer Chemotherapy and Pharmacology.

[42]  Jong-sang Park,et al.  Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. , 2002, Arthritis and rheumatism.

[43]  F. Hall,et al.  Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. , 2006, International journal of oncology.

[44]  F M Muggia,et al.  ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.

[45]  T. Ishihara,et al.  Treatment of experimental arthritis with poly(d, l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate , 2005, Annals of the rheumatic diseases.

[46]  Jagdish Singh,et al.  Poly (lactide-co-glycolide)-Polymethacrylate Nanoparticles for Intramuscular Delivery of Plasmid Encoding Interleukin-10 to Prevent Autoimmune Diabetes in Mice , 2008, Pharmaceutical Research.

[47]  Nakissa Sadrieh,et al.  Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. , 2009, Advanced drug delivery reviews.

[48]  J. C. Roberts,et al.  Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. , 1996, Journal of biomedical materials research.

[49]  Shraddha S. Nigavekar,et al.  Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine , 2008, PloS one.

[50]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[51]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[52]  R. Müller,et al.  Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. , 2001, International journal of pharmaceutics.

[53]  S W Burchiel,et al.  Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. , 2009, Nature nanotechnology.

[54]  Alfred N. Martin.  Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences , 1969 .

[55]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Wei Zhao,et al.  References Subscriptions Permissions Email Alerts Fullerene Nanomaterials Inhibit the Allergic Response , 2013 .

[57]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[58]  Martinus Løvik,et al.  Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[59]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[60]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[61]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[62]  P. Baron,et al.  Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[63]  F. Hall,et al.  Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. , 2007, International journal of oncology.

[64]  Scott E McNeil,et al.  Nanotechnology safety concerns revisited. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[66]  Ennio De Gregorio,et al.  The path to a successful vaccine adjuvant--'the long and winding road'. , 2009, Drug discovery today.

[67]  T. Ishida,et al.  Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. , 2008, International journal of pharmaceutics.

[68]  S M Moghimi,et al.  Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. , 2002, Biochimica et biophysica acta.

[69]  Y. Nodasaka,et al.  Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo. , 2005, Molecular bioSystems.

[70]  R. Whitham,et al.  Synthetic Peptide Dendrimers Block the Development and Expression of Experimental Allergic Encephalomyelitis1 , 2008, The Journal of Immunology.

[71]  Frank A Witzmann,et al.  Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes. , 2006, Nanomedicine : nanotechnology, biology, and medicine.